19 June 2025 Equity Research Report China Healthcare Equities Demand for innovative drug clinical trials shifting to China amid supportive policies China's clinical efficiency leap: Catching up with the world with strengthened competitiveness. The National Medical Product Administration (NMPA) published a circular in June, proposing to reduce the review and approval time of clinical trial applications for all innovative drugs to 30 days from the previous 60 days, following the pilot programme in July 2024. ...

Ardent Health Partners (ARDT) 2025 Conference May 20, 2025 08:00 AM ET Speaker0 Of Ardent Health Care Partners. We are, hosting Marty Bonnick, chief executive officer, and Alfred Lumsdain, chief financial officer. We also have in the room senior vice president investor relations, Dave Styblo. Welcome, guys. Thank you for joining us. Good to be here, Ben. Great. Maybe if you can kind of just open with a few words on your thoughts on the state of the world. Speaker1 Yeah. No. It's it's certainly been an inter ...

Financial Data and Key Metrics Changes - The preliminary voting results indicate that stockholders overwhelmingly approved all proposals, including the election of 10 directors and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm [12]. Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [11][14]. Market Data and Key Metrics Changes - There were no specific market data or key metrics changes mentioned in the meeting [11][14]. Company Strategy and Development Direction and Industry Competition - The meeting focused on the election of directors and the approval of compensation plans, indicating a stable governance structure and commitment to performance incentives [9][10]. Management's Comments on Operating Environment and Future Outlook - Management expressed gratitude towards employees for their dedication and hard work, emphasizing the company's commitment to being a leading healthcare provider [15][16]. Other Important Information - The meeting had no questions submitted from stockholders, indicating a lack of immediate concerns or inquiries regarding the company's operations or future plans [11][14]. Q&A Session All Questions and Answers Question: Were there any questions regarding the proposals? - No questions regarding the proposals were submitted through the annual meeting website [11]. Question: Were there any general questions about the business of the company? - No general questions were submitted through the annual meeting website [14].

DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-663 ...